Novavax Push For COVID-19 Vaccine Manufacturing Capacity Delays Flu Vaccine Application
Executive Summary
As CEO Erck touts that its COVID vaccine has the 'best data,' Novavax prepares to enter Phase III trials and inks deal with Serum Institute to boost production even as its 'almost a perfect flu vaccine' remains on hold.
You may also be interested in...
Novavax’s Vaccine Switched Manufacturing Facilities Multiple Times Prior To EUA
One switch raised questions, but by the time the COVID-19 vaccine reached commercial scale, the changes were considered minor.
Adolescent Recruitment For COVID-19 Vaccine Trials Is Worry For Operation Warp Speed
However, recruitment for adult trials remains robust, OWS’ Slaoui says.
Vaccine Distribution Priorities To Rely On Governors, Not ACIP, HHS Secretary Azar Says
Azar says ACIP’s prioritization recommendations should carry weight, but states will be final arbiter of who is vaccinated.